Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up - Summary - MDSpire

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • By

  • Eva Domingo-Domènech

  • Barbara Pro

  • Tim Illidge

  • Steven Horwitz

  • Lorenz Trumper

  • Swami Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Won-Seog Kim

  • Tatyana Feldman

  • Ilseung Choi

  • Giuseppe Gritti

  • David Belada

  • Andrei Shustov

  • Arpad Illes

  • Pier Luigi Zinzani

  • Andreas Hüttmann

  • Marek Trneny

  • Steven Le Gouill

  • Deepa Jagadeesh

  • Jonathan W. Friedberg

  • Meredith Little

  • Cassie Dong

  • Michelle Fanale

  • Keenan Fenton

  • Kerry J. Savage

  • January 28, 2026

  • 0 min

Share

Objective:

To clarify the 5-year progression-free survival (PFS) rates in patients with ALK– systemic anaplastic large cell lymphoma (sALCL) who achieved complete response (CR) in the context of the ECHELON-2 study.

Key Findings:
  • The estimated 5-year PFS rate for ALK– sALCL patients who achieved CR was 56.8% in the A + CHP arm and 56.0% in the CHOP arm.
Interpretation:

The correction emphasizes the importance of accurately reporting clinical outcomes based on patient response categories to avoid confusion in clinical interpretation.

Limitations:
  • The correction does not address other potential misinterpretations in the original article.
Conclusion:

The article has been corrected to ensure clarity regarding the 5-year PFS rates for patients with ALK– sALCL achieving CR.

Original Source(s)

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up

  • by Eva Domingo-Domènech, Barbara Pro, Tim Illidge, Steven Horwitz, Lorenz Trumper, Swami Iyer, Ranjana Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Won-Seog Kim, Tatyana Feldman, Ilseung Choi, Giuseppe Gritti, David Belada, Andrei Shustov, Arpad Illes, Pier Luigi Zinzani, Andreas Hüttmann, Marek Trneny, Steven Le Gouill, Deepa Jagadeesh, Jonathan W. Friedberg, Meredith Little, Cassie Dong, Michelle Fanale, Keenan Fenton, Kerry J. Savage

  • January 28, 2026

Related Content

Short-term cardiotoxicity and early echocardiographic changes following autologous hematopoietic stem cell transplantation: a single-center retrospective analysis

Delays in Hematology Consultations and Non-Hematology Referrals in Blood Cancer Diagnosis: Insights from a Comprehensive National Survey in Australia

Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure”